BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16405224)

  • 1. Appropriate antibiotic therapy for community-acquired respiratory tract infections.
    Gerbino PP; Brixner D; Sbarbaro J; Nicolau D
    Manag Care Interface; 2005 Dec; 18(12):41-8. PubMed ID: 16405224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections.
    Nicolau DP
    Am J Manag Care; 2000 Dec; 6(23 Suppl):S1202-10. PubMed ID: 11187444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective use of antibiotics in managed care.
    Giaquinta D
    Manag Care Interface; 2005 Dec; 18(12):35-6, 48. PubMed ID: 16405223
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of community acquired respiratory infections.
    Gupta BD; Parakh M; Arora A
    Indian J Pediatr; 2001 Apr; 68 Suppl 2():S39-49. PubMed ID: 11411377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary care challenges in the management of respiratory tract infections.
    JAAPA; 2006 Sep; Suppl():4-14; quiz 15-6. PubMed ID: 17001773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic resistance in community-acquired respiratory tract infections: current issues.
    Spach DH; Black D
    Ann Allergy Asthma Immunol; 1998 Oct; 81(4):293-302; quiz 302-3. PubMed ID: 9809491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory infections in the community. A concise update.
    Ferguson J
    Aust Fam Physician; 1998 Oct; 27(10):883-7. PubMed ID: 9798285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of community-acquired acute bacterial rhinosinusitis: the allergist's perspective.
    Meltzer EO; Weinstein SF; Zitt MJ
    Ann Allergy Asthma Immunol; 2006 Mar; 96(3):390-7. PubMed ID: 16597072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
    Rapp RP
    Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational use of antibiotics to treat respiratory tract infections.
    File TM; Hadley JA
    Am J Manag Care; 2002 Aug; 8(8):713-27. PubMed ID: 12212759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM; Tillotson G
    Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of managed care organizations in treating respiratory tract infections in an age of antibiotic resistance.
    Mogyoros M
    Am J Manag Care; 2001 Jun; 7(6 Suppl):S163-9. PubMed ID: 11424584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-duration therapy for respiratory tract infections.
    Goff DA
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical impact of antibiotic resistance in respiratory tract infections].
    Klugman K
    Med Mal Infect; 2007 Nov; 37 Spec No 1():6-10. PubMed ID: 18376503
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing acute lower respiratory tract infections in an era of antibacterial resistance.
    Volturo GA; Low DE; Aghababian R
    Am J Emerg Med; 2006 May; 24(3):329-42. PubMed ID: 16635707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract]   [Full Text] [Related]  

  • 19. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of resistance in the community.
    Eandi M; Zara GP
    Int J Clin Pract Suppl; 1998 Jun; 95():27-38. PubMed ID: 9796553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.